11:01:12 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-21 Ordinarie utdelning NYKD 0.00 NOK
2024-05-16 Årsstämma 2024
2024-05-14 Kvartalsrapport 2024-Q1
2024-02-28 Bokslutskommuniké 2023
2023-11-15 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-16 Kvartalsrapport 2023-Q1
2023-05-12 Ordinarie utdelning NYKD 0.00 NOK
2023-05-11 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-16 Kvartalsrapport 2022-Q1
2022-05-13 Ordinarie utdelning NYKD 0.00 NOK
2022-05-12 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning NYKD 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split NYKD 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Nykode Therapeutics är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.
2021-03-08 19:24:56
The following primary insiders/primary insider's related parties have today
bought 400,000 shares in Vaccibody AS at NOK 79.00 per share:

Datum AS 129,250
RASMUSSENGRUPPEN AS 129,250
Caaby AS 12,925
AS Tanja (Andenaesgruppen) 116,325
CF International ApS 12,250
Total 400,000

After the above transactions Jan Haudemann Andersen (board member) holds
40,263,050 shares (including 32,634,250 shares through Datum AS), Rasmussen
Group of companies holds 33,936,750 shares (of which RASMUSSENGRUPPEN AS,in
which Trygve Lauvdal (member of the VACCIBODY AS board) is an employee, owns
28,086,750), Christian Åbyholm (board member) through Caaby AS holds 1,995,895
shares and 100,000 warrants and Andenaesgruppen (through AS Tanja and
Christiania Skibs AS) represented by Christian Åbyholm owns 17,870,575 shares
and in addition Norda ASA represented by Christian Åbyholm owns 7,996,755 shares
and Caspar Foghsgaard, Director Business Development holds 392,000 warrants and
468,250 shares through CF International ApS (a company wholly owned by Caspar
Foghsgaard).

Due to a divorce process Primary insider CTO Mette Husbyn has exercised a total
of 400,000 warrants with two expiry dates, first of December 20, 2022 and the
second of December 31, 2022. 255,000 Vaccibody AS shares have been subscribed
for at a strike price of NOK 2,50 per share and 145,000 Vaccibody AS shares have
been subscribed for at a strike price of NOK 4,00 per share. The shares are
borrowed from Datum AS. The shares are borrowed and sold to the market price of
NOK 79.00 per share. Following the exercise of warrants Mette Husbyn holds
790,000 warrants.